Anti-CBL (phospho S669) antibody [EPR2226(2)] (ab108364)


  • Product nameAnti-CBL (phospho S669) antibody [EPR2226(2)]
    See all CBL primary antibodies
  • Description
    Rabbit monoclonal [EPR2226(2)] to CBL (phospho S669)
  • Specificityab108364 only detects Cbl phosphorylated at Serine 669.
  • Tested applicationsSuitable for: WBmore details
    Unsuitable for: Flow Cyt,ICC,IHC-P or IP
  • Species reactivity
    Reacts with: Mouse, Rat, Human
  • Immunogen

    A phospho specific peptide corresponding to residues surrounding Serine 669 of Human CBL.

  • Positive control
    • HeLa cells treated with pervanadate
  • General notes

    This product is a recombinant rabbit monoclonal antibody.

    Produced using Abcam’s RabMAb® technology. RabMAb® technology is covered by the following U.S. Patents, No. 5,675,063 and/or 7,429,487.


Our Abpromise guarantee covers the use of ab108364 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB 1/1000 - 1/10000. Predicted molecular weight: 100 kDa.
  • Application notesIs unsuitable for Flow Cyt,ICC,IHC-P or IP.
  • Target

    • FunctionParticipates in signal transduction in hematopoietic cells. Adapter protein that functions as a negative regulator of many signaling pathways that start from receptors at the cell surface. Acts as an E3 ubiquitin-protein ligase, which accepts ubiquitin from specific E2 ubiquitin-conjugating enzymes, and then transfers it to substrates promoting their degradation by the proteasome. Recognizes activated receptor tyrosine kinases, including PDGFA, EGF and CSF1, and terminates signaling.
    • PathwayProtein modification; protein ubiquitination.
    • Involvement in diseaseDefects in CBL are the cause of Noonan syndrome-like disorder (NSL) [MIM:613563]. NSL is a syndrome characterized by a phenotype reminiscent of Noonan syndrome. Clinical features are highly variable, including facial dysmorphism, short neck, developmental delay, hyperextensible joints and thorax abnormalities with widely spaced nipples. The facial features consist of triangular face with hypertelorism, large low-set ears, ptosis, and flat nasal bridge. Some patients manifest cardiac defects.
    • Sequence similaritiesContains 1 Cbl-PTB (Cbl-type phosphotyrosine-binding) domain.
      Contains 1 RING-type zinc finger.
      Contains 1 UBA domain.
    • DomainThe RING-type zinc finger domain mediates binding to an E2 ubiquitin-conjugating enzyme.
      The N-terminus is composed of the phosphotyrosine binding (PTB) domain, a short linker region and the RING-type zinc finger. The PTB domain, which is also called TKB (tyrosine kinase binding) domain, is composed of three different subdomains: a four-helix bundle (4H), a calcium-binding EF hand and a divergent SH2 domain.
    • Post-translational
      Phosphorylated on tyrosine residues by EGFR, SYK, FYN and ZAP70 (By similarity). Phosphorylated on tyrosine residues by INSR.
    • Cellular localizationCytoplasm.
    • Information by UniProt
    • Database links
    • Alternative names
      • 4732447J05Rik antibody
      • C CBL antibody
      • Cas Br M (murine) ecotropic retroviral transforming sequence antibody
      • Casitas B lineage lymphoma proto oncogene antibody
      • Casitas B-lineage lymphoma proto-oncogene antibody
      • CBL 2 antibody
      • cbl antibody
      • CBL_HUMAN antibody
      • CBL2 antibody
      • E3 ubiquitin protein ligase CBL antibody
      • E3 ubiquitin-protein ligase CBL antibody
      • Oncogene CBL2 antibody
      • Proto oncogene c CBL antibody
      • Proto-oncogene c-CBL antibody
      • RGD1561386 antibody
      • RING finger protein 55 antibody
      • RNF55 antibody
      • Signal transduction protein CBL antibody
      see all

    Anti-CBL (phospho S669) antibody [EPR2226(2)] images

    • All lanes : Anti-CBL (phospho S669) antibody [EPR2226(2)] (ab108364) at 1/1000 dilution

      Lane 1 : HeLa cell lysates, untreated
      Lane 2 : HeLa cell lysates, treated with pervanadate

      Lysates/proteins at 10 µg per lane.

      Predicted band size : 100 kDa

    References for Anti-CBL (phospho S669) antibody [EPR2226(2)] (ab108364)

    ab108364 has not yet been referenced specifically in any publications.

    Product Wall

    Abcam guarantees this product to work in the species/application used in this Abreview.
    Application Western blot
    Sample Human Cell lysate - whole cell (HEK293)
    Loading amount 30 µg
    Specification HEK293
    Treatment Activator
    Gel Running Conditions Reduced Denaturing (10%)
    Blocking step BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 4% · Temperature: 20°C

    Abcam user community

    Verified customer

    Submitted May 10 2013